tiprankstipranks
Brooklyn ImmunoTherapeutics (BTX)
NASDAQ:BTX
US Market

Brooklyn ImmunoTherapeutics (BTX) Income Statement

0 Followers

Brooklyn ImmunoTherapeutics Income Statement

Last quarter (Q ), Brooklyn ImmunoTherapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Brooklyn ImmunoTherapeutics's net income was $-3.41M. See Brooklyn ImmunoTherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20
Total Revenue
-$ 0.00$ 0.00
Cost of Revenue
---
Gross Profit
---
Operating Expense
$ 26.74M$ 26.77M$ 7.25M
Operating Income
$ -26.74M$ -26.77M$ -7.25M
Net Non Operating Interest Income Expense
$ -52.24K$ -74.00K$ -43.00K
Other Income Expense
$ -80.50M$ -95.64M$ -19.24M
Pretax Income
$ -107.29M$ -122.48M$ -26.53M
Tax Provision
$ 5.00K$ 64.00K$ 0.00
Earnings From Equity Interest Net Of Tax
---
Net Income Common Stockholders
$ -107.31M$ -122.56M$ -26.53M
Basic EPS
$ -3.23$ -56.40$ -1.51
Diluted EPS
$ -3.23$ -56.40$ -1.51
Basic Average Shares
$ 159.25M$ 2.17M$ 17.59M
Diluted Average Shares
$ 159.25M$ 2.17M$ 17.59M
Dividend Per Share
---
Total Operating Income As Reported
---
Reported Normalized Basic E P S
---
Reported Normalized Diluted E P S
---
Rent Expense Supplemental
---
Total Expenses
$ 26.74M$ 26.77M$ 7.25M
Net Income From Continuing And Discontinued Operation
$ -107.29M$ -122.55M$ -26.53M
Normalized Income
$ -27.95M$ -52.73M$ -7.29M
Interest Expense
$ 52.24K$ 74.00K$ 43.00K
EBIT
$ -107.23M$ -122.41M$ -26.49M
EBITDA
$ -106.70M$ -121.95M$ -26.39M
Currency in USD

Brooklyn ImmunoTherapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis